HRP20131104T1 - Metoda širenja za odrasle matiäśne stanice iz krvi, posebno periferne krvi, te relativna uporaba u medicinskom podruäśju - Google Patents
Metoda širenja za odrasle matiäśne stanice iz krvi, posebno periferne krvi, te relativna uporaba u medicinskom podruäśju Download PDFInfo
- Publication number
- HRP20131104T1 HRP20131104T1 HRP20131104TT HRP20131104T HRP20131104T1 HR P20131104 T1 HRP20131104 T1 HR P20131104T1 HR P20131104T T HRP20131104T T HR P20131104TT HR P20131104 T HRP20131104 T HR P20131104T HR P20131104 T1 HRP20131104 T1 HR P20131104T1
- Authority
- HR
- Croatia
- Prior art keywords
- mammals
- stem cells
- concentration
- mcsf
- recommended
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 210000004504 adult stem cell Anatomy 0.000 title claims 5
- 210000004369 blood Anatomy 0.000 title claims 4
- 239000008280 blood Substances 0.000 title claims 4
- 210000005259 peripheral blood Anatomy 0.000 title claims 2
- 239000011886 peripheral blood Substances 0.000 title claims 2
- 241000124008 Mammalia Species 0.000 claims 9
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 6
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 241000167854 Bourreria succulenta Species 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010027925 Monoparesis Diseases 0.000 claims 2
- 208000006735 Periostitis Diseases 0.000 claims 2
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 2
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000019693 cherries Nutrition 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000003041 ligament Anatomy 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000003071 parasitic effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 231100000444 skin lesion Toxicity 0.000 claims 2
- 206010040882 skin lesion Diseases 0.000 claims 2
- 210000002435 tendon Anatomy 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 229920001917 Ficoll Polymers 0.000 claims 1
- 208000001762 Gastric Dilatation Diseases 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Claims (14)
1. Metoda za širenje odraslih matičnih stanica iz krvi, posebno ali ne isključivo periferne krvi, koja sadrži slijedeće korake:
a) prvi korak širenja matičnih stanica krvi, odmah nakon što su uzete iz pacijenta, pomoću in-vitro tretmana sa MCSF u koncentraciji sadržanoj između 8-15 nM te
b) drugi korak pročišćavanja proširene matične stanice.
c) širenje matičnih stanica krvi pročišćenih u koraku b) pomoću in-vitro tretmana sa MCSF u koncentraciji sadržanoj između oko 35-55 nM kroz 24-72 sata.
2. Metoda kao u patentnom zahtjevu 1, naznačena time da spomenuti in-vitro korak a) sa MCSF ima trajanje sadržano između 24 i 96 sati.
3. Metoda kao u patentnom zahtjevu 1, naznačena time da spomenuti in-vitro korak a) sa MCSF ima trajanje sadržano između 48 i 72 sata.
4. Metoda kao u patentnom zahtjevu 1, naznačena time da in-vitro tretman u koraku a) započinje ne više od 10 minuta nakon uzimanja uzorka, a najbolje ne više od 5 minuta.
5. Metoda kao u bilo kojem prethodnom zahtjevu, gdje je spomenuta koncentracija MCSF u koraku a) preporučeno 10 nM.
6. Metoda kao u patentnom zahtjevu 1, gdje je spomenuta koncentracija MCSF u koraku c) preporučeno 50 nM, te još preporučenije 45 nM.
7. Metoda kao u bilo kojem prethodnom zahtjevu, gdje da in-vitro tretman u koraku a) i/ili koraku c) traje 24-48 sati, preporučeno 45-48 sati.
8. Metoda kao u bilo kojem prethodnom zahtjevu, gdje dolazi do koraka pročišćavanja b) pomoću frakcioniranja na Ficoll gradijentu.
9. Farmaceutski pripravak koji sadrži odrasle matične stanice dobivene prema metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 u koncentraciji sadržanoj između 90-250×103 stanica/mL, kao aktivnu tvar, zajedno sa farmakološki prihvatljivim adjuvansima i/ili ekscipijensima, pri čemu se spomenuti pripravak formulira za intravenoznu injekciju, za uporabu u liječenju lezija izabranih iz skupine koja sadrži kožne lezije, lezije tetiva, ligamenata, kostiju, mukozne membrane u sisavcima, ili fraktura, neuroloških ili neurodegenerativnih patologija izabranih iz skupine koja se sastoji od Cushingove bolesti, trešnje glave, Wobblerovog sindroma, teškoća s disanjem, pareze udova u sisavcima, akutnih i kroničnih upalnih patologija izabranih iz laminitisa, periostitisa, gastritisa, artroze, upala uzrokovanih virusnim, bakterijskim, parazitskim, mikotskim agensima u sisavcima, sindroma dilatacije-torzije želuca u sisavcima.
10. Farmaceutski pripravak koji sadrži odrasle matične stanice dobivene prema metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 u koncentraciji sadržanoj između 4-40×106 stanica/mL, preporučeno 7×106 stanica/mL, kao aktivnu tvar, zajedno sa farmakološki prihvatljivim adjuvansima i/ili ekscipijensima, pri čemu se spomenuti pripravak formulira za lokalnu primjenu, za uporabu u liječenju lezija izabranih iz skupine koja sadrži kožne lezije, lezije tetiva, ligamenata, kostiju, mukozne membrane u sisavcima, ili fraktura, neuroloških ili neurodegenerativnih patologija izabranih iz skupine koja se sastoji od Cushingove bolesti, trešnje glave, Wobblerovog sindroma, teškoća s disanjem, pareze udova u sisavcima, akutnih i kroničnih upalnih patologija izabranih iz laminitisa, periostitisa, gastritisa, artroze, upala uzrokovanih virusnim, bakterijskim, parazitskim, mikotskim agensima u sisavcima, sindroma dilatacije-torzije želuca u sisavcima.
11. Spoj za uporabu kao u patentnom zahtjevu 10, koji također sadrži antibiotik kao aktivnu tvar u koncentraciji sadržanoj između 5-15 nM, preporučeno 10 nM.
12. Pripravak za uporabu prema patentnom zahtjevu 11, gdje je antibiotik gentamicin.
13. Pripravak za uporabu prema patentnom zahtjevu 9, pri čemu spomenuti pripravak sadrži odrasle matične stanice dobivene u koncentraciji jednakoj 150×103 stanica/ mL te se administrira intravenozno jednom tjedno.
14. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 9 do 13, gdje su spomenuti sisavci izabrani od ljudi, konja, mačaka ili pasa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000498A ITRM20060498A1 (it) | 2006-09-20 | 2006-09-20 | Metodo di espansione di cellule staminali adulte da sangue periferico e relativi usi in campo medico |
| PCT/EP2007/059531 WO2008034740A1 (en) | 2006-09-20 | 2007-09-11 | Expansion method for adult stem cells from blood, particularly peripheral blood, and relative application in medical field |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131104T1 true HRP20131104T1 (hr) | 2013-12-20 |
Family
ID=38126399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131104TT HRP20131104T1 (hr) | 2006-09-20 | 2013-11-19 | Metoda širenja za odrasle matiäśne stanice iz krvi, posebno periferne krvi, te relativna uporaba u medicinskom podruäśju |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8263400B2 (hr) |
| EP (1) | EP2076588B1 (hr) |
| JP (1) | JP5340941B2 (hr) |
| KR (1) | KR101570446B1 (hr) |
| CN (1) | CN101553565B (hr) |
| AU (1) | AU2007299043B2 (hr) |
| BR (1) | BRPI0715036A2 (hr) |
| CA (1) | CA2663072C (hr) |
| DK (1) | DK2076588T3 (hr) |
| EA (1) | EA019305B1 (hr) |
| ES (1) | ES2435080T3 (hr) |
| HK (1) | HK1138315A1 (hr) |
| HR (1) | HRP20131104T1 (hr) |
| IL (1) | IL197575A (hr) |
| IT (1) | ITRM20060498A1 (hr) |
| MX (1) | MX2009003059A (hr) |
| PL (1) | PL2076588T3 (hr) |
| RS (1) | RS53039B (hr) |
| SI (1) | SI2076588T1 (hr) |
| WO (1) | WO2008034740A1 (hr) |
| ZA (1) | ZA200901748B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9132116B2 (en) | 2004-08-02 | 2015-09-15 | Willowcroft Pharm Inc. | Mast cell stabilizers to prevent or treat laminitis |
| ITUD20080058A1 (it) * | 2008-03-18 | 2009-09-19 | Thankstem S R L | Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali |
| WO2010126544A1 (en) * | 2009-04-29 | 2010-11-04 | Willowcroft Pharm, Llc | Mast cell stabilizers to prevent or treat laminitis |
| KR101202836B1 (ko) * | 2010-08-27 | 2012-11-20 | 서울대학교산학협력단 | 세포응집을 이용한 인간 혈액 유래 혈구 세포괴의 유도와 이를 이용한 혈중 성체줄기세포 및 전구세포의 증폭방법 및 상기의 방법에 의해 제조된 줄기세포 |
| CN103781486A (zh) * | 2011-01-31 | 2014-05-07 | 皇家医学集团专业有限责任公司 | 多能干细胞和刺激并从哺乳动物血液提取非胚胎多能干细胞和使用复原多能干细胞治疗包括慢性阻塞性肺病的疾病的方法 |
| BE1020480A5 (nl) * | 2012-10-01 | 2013-11-05 | Global Stem Cell Technology | Werkwijze voor de isolatie van mesenchymale stamcellen uit bloed van zoogdieren, en gebruik ervan. |
| CA2948096A1 (en) * | 2014-05-09 | 2015-11-12 | Marco Polettini | Method for expanding adult stem cells from whole blood |
| RU2644650C2 (ru) | 2014-12-01 | 2018-02-13 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток и способ его получения |
| WO2016204230A1 (ja) * | 2015-06-17 | 2016-12-22 | 仁幸 小林 | 幹細胞投与方法、競走馬または競技馬の症状改善方法、注射用容器および幹細胞注射セット |
| RU2708329C2 (ru) | 2016-05-31 | 2019-12-05 | Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" | Материал стволовых клеток, композиции и способы применения |
| RU2771328C2 (ru) * | 2016-06-23 | 2022-04-29 | Титон Биотек, Инк. | Клетки, экспрессирующие рецептор паратиреоидного гормона 1, и их применение |
| US11103537B2 (en) | 2016-06-23 | 2021-08-31 | Tithon Biotech Inc. | Cells expressing parathyroid hormone 1 receptor and uses thereof |
| AU2020277774A1 (en) * | 2019-05-22 | 2021-12-09 | Thankstem S.R.L. | Method for expanding adult stem cells from whole blood |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1436843A (zh) * | 2002-02-08 | 2003-08-20 | 刘颉 | 脐血造血干细胞的制作方法 |
| TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| EP2357223A3 (en) | 2002-11-07 | 2012-11-07 | University Of Chicago | Human stem cell material and methods |
| CN1667119A (zh) * | 2004-03-11 | 2005-09-14 | 中国人民解放军第二军医大学 | 一种成体干细胞及其培养方法和用途 |
-
2006
- 2006-09-20 IT IT000498A patent/ITRM20060498A1/it unknown
-
2007
- 2007-09-11 EA EA200970294A patent/EA019305B1/ru not_active IP Right Cessation
- 2007-09-11 PL PL07820134T patent/PL2076588T3/pl unknown
- 2007-09-11 ES ES07820134T patent/ES2435080T3/es active Active
- 2007-09-11 RS RS20130499A patent/RS53039B/en unknown
- 2007-09-11 AU AU2007299043A patent/AU2007299043B2/en not_active Ceased
- 2007-09-11 EP EP07820134.0A patent/EP2076588B1/en active Active
- 2007-09-11 DK DK07820134.0T patent/DK2076588T3/da active
- 2007-09-11 BR BRPI0715036-9A patent/BRPI0715036A2/pt not_active Application Discontinuation
- 2007-09-11 CA CA2663072A patent/CA2663072C/en active Active
- 2007-09-11 WO PCT/EP2007/059531 patent/WO2008034740A1/en active Application Filing
- 2007-09-11 KR KR1020097007818A patent/KR101570446B1/ko active IP Right Grant
- 2007-09-11 SI SI200731352T patent/SI2076588T1/sl unknown
- 2007-09-11 JP JP2009528679A patent/JP5340941B2/ja active Active
- 2007-09-11 CN CN200780034935.XA patent/CN101553565B/zh active Active
- 2007-09-11 MX MX2009003059A patent/MX2009003059A/es active IP Right Grant
-
2009
- 2009-03-11 ZA ZA200901748A patent/ZA200901748B/xx unknown
- 2009-03-12 IL IL197575A patent/IL197575A/en active IP Right Grant
- 2009-03-20 US US12/408,145 patent/US8263400B2/en active Active
-
2010
- 2010-04-07 HK HK10103425.7A patent/HK1138315A1/xx unknown
-
2012
- 2012-08-16 US US13/587,417 patent/US20120308535A1/en not_active Abandoned
-
2013
- 2013-11-19 HR HRP20131104TT patent/HRP20131104T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120308535A1 (en) | 2012-12-06 |
| HK1138315A1 (en) | 2010-08-20 |
| ITRM20060498A1 (it) | 2008-03-21 |
| ES2435080T3 (es) | 2013-12-18 |
| PL2076588T3 (pl) | 2014-01-31 |
| IL197575A (en) | 2013-06-27 |
| RS53039B (en) | 2014-04-30 |
| SI2076588T1 (sl) | 2013-12-31 |
| WO2008034740A1 (en) | 2008-03-27 |
| ZA200901748B (en) | 2010-03-31 |
| KR20090074044A (ko) | 2009-07-03 |
| DK2076588T3 (da) | 2013-11-11 |
| CN101553565B (zh) | 2015-05-06 |
| AU2007299043B2 (en) | 2013-06-27 |
| EP2076588B1 (en) | 2013-08-21 |
| JP5340941B2 (ja) | 2013-11-13 |
| IL197575A0 (en) | 2011-08-01 |
| JP2010504083A (ja) | 2010-02-12 |
| CA2663072C (en) | 2016-01-19 |
| EP2076588A1 (en) | 2009-07-08 |
| EA200970294A1 (ru) | 2009-10-30 |
| EA019305B1 (ru) | 2014-02-28 |
| CA2663072A1 (en) | 2008-03-27 |
| AU2007299043A1 (en) | 2008-03-27 |
| US20100068189A1 (en) | 2010-03-18 |
| BRPI0715036A2 (pt) | 2013-05-28 |
| MX2009003059A (es) | 2009-04-01 |
| CN101553565A (zh) | 2009-10-07 |
| KR101570446B1 (ko) | 2015-11-27 |
| US8263400B2 (en) | 2012-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131104T1 (hr) | Metoda širenja za odrasle matiäśne stanice iz krvi, posebno periferne krvi, te relativna uporaba u medicinskom podruäśju | |
| Yamanaka et al. | Preventive effects of dexmedetomidine on the development of cognitive dysfunction following systemic inflammation in aged rats | |
| Xu et al. | Mast cells involvement in the inflammation and fibrosis development of the TNBS-induced rat model of colitis | |
| JP2010504083A5 (hr) | ||
| BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| KR101401744B1 (ko) | Ｎ-아세틸-ｌ-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물 | |
| WO2022042541A1 (zh) | 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用 | |
| JP2021527669A (ja) | 線維症の軽減又は治療のための組成物及び方法 | |
| Muzika et al. | Histological study of isoniazid-rifampicin related nephrotoxicity in Wistar rats | |
| EP2528595A1 (de) | Verbindungen zur verwendung bei der behandlung von erkrankungen | |
| US11980624B2 (en) | Methods for administering compositions comprising hydroxytyrosol and boswellic acid | |
| JP2006241051A (ja) | 抗ストレス剤 | |
| US10342802B2 (en) | Compositions comprising hydroxytyrosol and boswellic acid | |
| WO2021202523A1 (en) | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy | |
| TWI531366B (zh) | 牛樟芝在關節炎、軟骨破壞或軟骨細胞死亡的改善或預防的功效 | |
| Raghu et al. | Evaluation of in-vitro and in-vivo anti-inflammatory activities of apigenin and vitexin | |
| US20070060604A1 (en) | Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment | |
| TW201720461A (zh) | 預防或治療脂肪胰、改善脂肪胰引起的胰病變、糖尿病或其他相關病症之組合物及方法 | |
| CA2441629C (en) | Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment | |
| WO2024035859A1 (en) | Combination therapies for treating inflammation | |
| TWI645083B (zh) | 篩選抑制發炎反應及血管保護活性物質之方法 | |
| JP2009235035A (ja) | アレルギー性気管支喘息抑制剤 | |
| CA3219596A1 (en) | Compositions and uses therefor | |
| JP2004231599A (ja) | 新規なリウマチ様関節炎の治療剤 | |
| TW202416945A (zh) | 用於治療發炎之組合療法 |